CD24 ala57Val polymorphism predicts pathologic complete response to sequential anthracycline- and taxane-based neoadjuvant chemotherapy for primary breast cancer

Breast Cancer Research and Treatment

Volumn 132, Issue 3, 2012, Pages 819-831

  Marmé, Frederik ^a,b   Werft, Wiebke ^b   Walter, Anne ^c   Keller, Sascha ^b   Wang, Xiaoli ^b   Benner, Axel ^b   Burwinkel, Barbara ^a,b   Sinn, Peter ^d   Hug, Sarah ^a   Sohn, Christof ^a   Bretz, Niko ^b   Moldenhauer, Gerhard ^b   Rupp, Christian ^b   Rupp, Anne Kathleen ^b   Biakhov, Mikhail Y ^e   Bottini, Alberto ^f   Friedrichs, Kay ^g   Khailenko, V A ^h   Manikhas, Georgiy M ⁱ   Ruiz, Amparo ^j   Sánchez Rovira, Pedro ^k   Santoro, Armando ^l   Segui, Miguel A ^m   Villena, Carlos ⁿ   Lichter, Peter ^b   Kristiansen, Glen ^c   Altevogt, Peter ^b   Schneeweiss, Andreas ^a   more..

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY OF ZURICH   (Switzerland)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e Central Hospital of MPS RF   (Russian Federation)

^f CREMONA HOSPITAL   (Italy)

^g Jerusalem Hospital   (Germany)

^h N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

ⁱ City Oncology Dispensary St Petersburg   (Russian Federation)

^j INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^k Medical Oncology Department   (Spain)

^l HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^m Servicio de Cirugía General Y Aparato Digestivo   (Spain)

ⁿ Klinikum Mittelbaden   (Germany)

more..

Author keywords

Neoadjuvant chemotherapy; Pathologic complete response; PCR; Polymorphism; Predictive marker; Primary breast cancer; SNP

Indexed keywords

ALANINE; CD24 ANTIGEN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; MESSENGER RNA; PEMETREXED; VALINE; ANTINEOPLASTIC AGENT; CD24 PROTEIN, HUMAN; CD45 ANTIGEN; DRUG DERIVATIVE; GLUTAMIC ACID DERIVATIVE; GUANINE; PTPRC PROTEIN, HUMAN; TAXOID;

3' UNTRANSLATED REGION; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER STAGING; CD24 GENE; CHEMOSENSITIVITY; CLINICAL EVALUATION; CLINICAL FEATURE; DRUG DOSE SEQUENCE; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GERM LINE; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PRIMARY TUMOR; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; TUMOR GENE; TUMOR VOLUME; ADJUVANT THERAPY; AMINO ACID SUBSTITUTION; BREAST TUMOR; CANCER INVASION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; LYMPHOCYTE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; NONPARAMETRIC TEST; PATHOLOGY; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TUMOR CELL LINE;

AMINO ACID SUBSTITUTION; ANTIGENS, CD24; ANTIGENS, CD45; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL LINE, TUMOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; GENOTYPE; GLUTAMATES; GUANINE; HUMANS; LYMPHOCYTES; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; POLYMORPHISM, GENETIC; SEQUENCE ANALYSIS, DNA; STATISTICS, NONPARAMETRIC; TAXOIDS; TREATMENT OUTCOME;

EID: 84865161157     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1759-9     Document Type: Article

References (62)

1. Athanassiadou P, Grapsa D, Gonidi M, Athanassiadou A, Tsipis A, Patsouris E (2009) CD24 expression has a prognostic impact in breast carcinoma. Pathol Res Pract 205(8):524-533
2. Fogel M, Friederichs J, Zeller Y, Husar M, Smirnov A, Roitman L et al (1999) CD24 is a marker for human breast carcinoma. Cancer Lett 143(1):87-94
3. Jacob J, Bellach J, Grutzmann R, Alldinger I, Pilarsky C, Dietel M et al (2004) Expression of CD24 in adenocarcinomas of the pancreas correlates with higher tumor grades. Pancreatology 4(5):454-460
4. Kristiansen G, Denkert C, Schluns K, Dahl E, Pilarsky C, Hauptmann S (2002) CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival. Am J Pathol 161(4):1215-1221
5. Kristiansen G, Pilarsky C, Pervan J, Sturzebecher B, Stephan C, Jung K et al (2004) CD24 expression is a significant predictor of PSA relapse, poor prognosis in low grade or organ confined prostate cancer. Prostate 58(2):183-192
6. Kristiansen G, Schluns K, Yongwei Y, Denkert C, Dietel M, Petersen I (2003) CD24 is an independent prognostic marker of survival in nonsmall cell lung cancer patients. Br J Cancer 88(2):6-231
7. Kristiansen G, Winzer KJ, Mayordomo E, Bellach J, Schluns K, Denkert C et al (2003) CD24 expression is a new prognostic marker in breast cancer. Clin Cancer Res 9(13):4906-4913
8. Surowiak P, Materna V, Gyorffy B, Matkowski R, Wojnar A, Maciejczyk A et al (2006) Multivariate analysis of oestrogen receptor alpha, pS2, metallothionein and CD24 expression in invasive breast cancers. Br J Cancer 95(3):339-346
9. Surowiak P, Materna V, Kaplenko I, Spaczynski M, Dietel M, Kristiansen G et al (2006) Unfavorable prognostic value of CD24 expression in sections from primary and relapsed ovarian cancer tissue. Int J Gynecol Cancer 16(2):515-521
10. Weichert W, Denkert C, Burkhardt M, Gansukh T, Bellach J, Altevogt P et al (2005) Cytoplasmic CD24 expression in colorectal cancer independently correlates with shortened patient survival. Clin Cancer Res 11(18):6574-6581
11. Winkler A, Zigeuner R, Rehak P, Hutterer G, Chromecki T, Langner C (2007) CD24 expression in urothelial carcinoma of the upper urinary tract correlates with tumour progression. Virchows Arch 450(1):59-64
12. Yang XR, Xu Y, Yu B, Zhou J, Li JC, Qiu SJ et al (2009) CD24 is a novel predictor for poor prognosis of hepatocellular carcinoma after surgery. Clin Cancer Res 15(17):5518-5527
13. Surowiak P, Materna V, Paluchowski P, Matkowski R, Wojnar A, Maciejczyk A et al (2006) CD24 expression is specific for tamoxifen-resistant ductal breast cancer cases. Anticancer Res 26(1 B):629-634
14. Smith SC, Oxford G, Wu Z, Nitz MD, Conaway M, Frierson HF et al (2006) The metastasis-associated gene CD24 is regulated by Ral GTPase and is a mediator of cell proliferation and survival in human cancer. Cancer Res 66(4):1917-1922
15. Surowiak P, Materna V, Klak K, Spaczynski M, Dietel M, Kristiansen G et al (2005) Prognostic value of immunohistochemical estimation of CD24 and Ki67 expression in cisplatin and paclitaxel treated ovarian carcinoma patients. Pol J Pathol 56(2):69-74
16. Baumann P, Cremers N, Kroese F, Orend G, Chiquet-Ehrismann R, Uede T et al (2005) CD24 expression causes the acquisition of multiple cellular properties associated with tumor growth and metastasis. Cancer Res 65(23):10783-10793
17. Schindelmann S, Windisch J, Grundmann R, Kreienberg R, Zeillinger R, Deissler H (2002) Expression profiling of mammary carcinoma cell lines: correlation of in vitro invasiveness with expression of CD24. Tumor Biol 23(3):139
18. Aigner S, Ramos CL, Hafezi-moghadam A, Lawrence MB, Friederichs J, Altevogt P et al (1998) CD24 mediates rolling of breast carcinoma cells on P-selectin. FASEB J 12(12):1241-1251
19. Aigner S, Sthoeger ZM, Fogel M, Weber E, Zarn J, Ruppert M et al (1997) CD24, a mucin-type glycoprotein, is a ligand for P-Selectin on human tumor cells. Blood 89(9):3385-3395
20. Kristiansen G, Sammar M, Altevogt P (2004) Tumour biological aspects of CD24, a mucin-like adhesion molecule. J Mol Histol 35(3):255-262
21. Schabath H, Runz S, Joumaa S, Altevogt P (2006) CD24 affects CXCR4 function in pre-B lymphocytes and breast carcinoma cells. J Cell Sci 119(2):314-325
22. Li D, Zheng L, Jin L, Zhou Y, Li H, Fu J et al (2009) CD24 polymorphisms affect risk and progression of chronic hepatitis B virus infection. Hepatology 50:735-742
23. Liu Y, Wenger RH, Zhao M, Nielsen PJ (1997) Distinct costimulatory molecules are required for the induction of effector and memory cytotoxic T lymphocytes. J Exp Med 185(2):251-262
24. Bai XF, Li O, Zhou Q, Zhang H, Joshi PS, Zheng X et al (2004) CD24 controls expansion and persistence of autoreactive T cells in the central nervous system during experimental autoimmune encephalomyelitis. J Exp Med 200(4):447-458
25. Fang X, Zheng P, Tang J, Liu Y (2010) CD24: from A to Z. Cell Mol Immunol 7(2):100-103
26. Carl JW Jr, Liu JQ, Joshi PS, El-Omrani HY, Yin L, Zheng X et al (2008) Autoreactive T cells escape clonal deletion in the thymus by a CD24-dependent pathway. J Immunol 181(1):320-328
27. Askew D, Harding CV (2008) Antigen processing and CD24 expression determine antigen presentation by splenic CD4+ and CD8+ dendritic cells. Immunology 123(3):447-455
28. Liu Y, Zheng P (2007) CD24: a genetic checkpoint in T cell homeostasis and autoimmune diseases. Trends Immunol 28(7):315-320
29. Otaegui D, Saenz A, Camano P, Blazquez L, Goicoechea M, Ruiz-Martinez J et al (2006) CD24 V/V is an allele associated with the risk of developing multiple sclerosis in the Spanish population. Mult Scler 12(4):511-514
30. Sanchez E, Abelson AK, Sabio JM, Gonzalez-Gay MA, Ortego-Centeno N, Jimenez-Alonso J et al (2007) Association of a CD24 gene polymorphism with susceptibility to systemic lupus erythematosus. Arthritis Rheum 56(9):3080-3086
31. Wang L, Lin S, Rammohan KW, Liu Z, Liu JQ, Liu RH et al (2007) A dinucleotide deletion in CD24 confers protection against autoimmune diseases. PLoS Genet 3(4):e49
32. Zhou Q, Rammohan K, Lin S, Robinson N, Li O, Liu X et al (2003) CD24 is a genetic modifier for risk and progression of multiple sclerosis. PNAS 100(25):15041-15046
33. Rueda B, Miranda-Filloy JA, Martin J, Gonzalez-Gay MA (2008) Association of CD24 gene polymorphisms with susceptibility to biopsy-proven giant cell arteritis. J Rheumatol 35(5):850-854
34. Ronaghi M, Vallian S, Etemadifar M (2009) CD24 gene polymorphism is associated with the disease progression and susceptibility to multiple sclerosis in the Iranian population. Psychiatry Res 170:271-272
35. Denkert C, Loibl S, Noske A, Roller M, Muller BM, Komor M et al (2009) Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 27:4693-4700
36. Esserman LJ, Perou C, Cheang M, De Michele A, Carey L, Van't Veer LJ et al (2009) Breast cancer molecular profiles and tumor response of neoadjuvant doxorubicin and paclitaxel: The I-SPY TRIAL CALGB 150007/150012, ACRIN 6657. J Clin Oncol 27((15S)):LBA515 (Meeting Abstracts)
37. Tesniere A, Schlemmer F, Boige V, Kepp O, Martins I, Ghiringhelli F et al (2009) Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 29(4):482-491
38. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A et al (2007) Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 13(9):1050-1059
39. Apetoh L, Ghiringhelli F, Tesniere A, Criollo A, Ortiz C, Lidereau R et al (2007) The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev 220:47-59
40. Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA et al (2008) Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26(8):1275-1281
41. Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A et al (2008) Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 26(5):778-785
42. Guarneri V, Broglio K, Kau SW, Cristofanilli M, Buzdar AU, Valero V et al (2006) Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 24(7):1037-1044
43. Schneeweiss A, Marme F, Ruiz A, Manikhas AG, Bottini A, Wolf M et al (2010) A randomized phase II trial of doxorubicin plus pemetrexed followed by docetaxel versus doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant treatment of early breast cancer. Ann Oncol 124(2):403-412
44. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205-216
45. Gast D, Riedle S, Issa Y, Pfeifer M, Beckhove P, Sanderson MP et al (2008) The cytoplasmic part of L1-CAM controls growth and gene expression in human tumors that is reversed by therapeutic antibodies. Oncogene 27(9):1281-1289 [Research Support, Non-U. S. Gov't]
46. van Buuren BJ, Groothuis-Oudshoorn CGM, Rubin DB (2006) Fully conditional specifications in multivariate imputation. J Stat Comput Simul 76(12):1049-1064
47. Strasser HW, Weber C (1999) On the asymptotic theory of permutation statistics. Math Methods Stat 8:220-250
48. Hennessy BT, Hortobagyi GN, Rouzier R, Kuerer H, Sneige N, Buzdar AU et al (2005) Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J Clin Oncol 23(36):9304-9311
49. Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K et al (1999) Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17(2):460
50. Schroth W, Antoniadou L, Fritz P, Schwab M, Muerdter T, Zanger UM et al (2007) Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol 25(33):5187-5193
51. Xu Y, Yao L, Ouyang T, Li J, Wang T, Fan Z et al (2005) p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer. Clin Cancer Res 11(20):7328-7333
52. Marme F, Werft W, Benner A, Burwinkel B, Sinn P, Sohn C et al (2010) FGFR4 Arg388 genotype is associated with pathological complete response to neoadjuvant chemotherapy for primary breast cancer. Ann Oncol 21(8):1636-1642
53. Green H, Soderkvist P, Rosenberg P, Horvath G, Peterson C (2006) mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy. Clin Cancer Res 12(3 Pt 1):854-859
54. Green H, Soderkvist P, Rosenberg P, Horvath G, Peterson C (2008) ABCB1 G1199A polymorphism and ovarian cancer response to paclitaxel. J Pharm Sci 97(6):2045-2048
55. Goris A, Maranian M, Walton A, Yeo TW, Ban M, Gray J et al (2006) CD24 Ala/Val polymorphism and multiple sclerosis. J Neuroimmunol 175(1-2):200-202
56. Zitvogel L, Kepp O, Kroemer G (2010) Decoding cell death signals in inflammation and immunity. Cell 140(6):798-804
57. Tesniere A, Panaretakis T, Kepp O, Apetoh L, Ghiringhelli F, Zitvogel L et al (2008) Molecular characteristics of immunogenic cancer cell death. Cell Death Differ 15(1):3-12
58. Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C et al (2009) Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 15(10):1170-1178
59. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL et al (2007) Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13(1):54-61
60. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G (2008) Immunological aspects of cancer chemotherapy. Nat Rev Immunol 8(1):59-73
61. Zitvogel L, Kepp O, Kroemer G (2011) Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol 8(3):151-160
62. Chen GY, Tang J, Zheng P, Liu Y (2009) CD24 and Siglec-10 selectively repress tissue damage-induced immune responses. Science 323(5922):1722-1725 [Research Support, N. I. H., Extramural Research Support, Non-U. S. Gov't Research Support, U. S. Gov't, Non-P. H. S.]